Skip to main content

Table 4 Toxicities in patients aged more than 60 years who received h-R3/RT or CDDP/RT. (N = 14)

From: A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma

Toxicities (RTOG Grade) h-R3/RT (N = 7) [n (%)] CDDP/RT (N = 7) [n (%)] P Value*
WBC    0.102
 (1&2) 3 (42.9%) 5 (71.4%)  
 (3&4) 0 (0.00%) 0 (0.00%)  
PLT    0.059
 (1&2) 5 (71.4%) 1 (14.3%)  
 (3&4) 0 (0.00%) 0 (0.00%)  
HB    0.157
 (1&2) 2 (28.6%) 5 (71.4%)  
 (3&4) 0 (0.00%) 0 (0.00%)  
ALT    0.317
 (1&2) 0 (0.00%) 1 (14.3%)  
 (3&4) 0 (0.00%) 0 (0.00%)  
AST    0.317
 (1&2) 0 (0.00%) 1 (14.3%)  
 (3&4) 0 (0.00%) 0 (0.00%)  
GGT    1.000
 (1&2) 0 (0.00%) 0 (0.00%)  
 (3&4) 0 (0.00%) 0 (0.00%)  
Dermatitis    0.317
 (1&2) 4 (57.1%) 7 (100%)  
 (3&4) 0 (0.00%) 0 (0.00%)  
Rash    1.000
 (1&2) 0 (0.00%) 0 (0.00%)  
 (3&4) 0 (0.00%) 0 (0.00%)  
Mucositis    0.891
 (1&2) 2 (28.6%) 3 (42.9%)  
 (3&4) 4 (57.1%) 2 (52.4%)  
Taste change    1.000
 yes 5 (71.4%) 6 (85.7%)  
 no 2 (28.6%) 1 (14.3%)  
Vomit    0.020
 only nausea 0 (0.00%) 1 (2.4%)  
 Nausea and vomit 0 (0.00%) 5 (71.4%)  
Weight loss    0.174
 (1&2) 2 (28.6%) 4 (57.1%)  
 (3&4) 1 (14.3%) 2 (26.2%)  
  1. Abbreviations: RT radiotherapy, h-R3/RT nimotuzumab and radiotherapy, CDDP/RT cisplatin and radiotherapy
  2. * All p values were obtained by use of the paired rank sum test
\